Climate change poses a significant risk to public health globally. In fact, climate-generated natural disasters could lead to 14.5 million additional deaths and $12.5 trillion in economic losses by 2050. Several diseases, including malaria, dengue, asthma, heat-related illnesses, hypertension, stunting, and PTSD could see sizeable increases.
Addressing the looming health crisis requires strong public-private collaboration, innovative funding, and harmonized regulatory frameworks. Speaking with Oliver Wyman’s Terry Stone and Dr. Oliver Eitelwein during the World Economic Forum’s annual meeting in Davos, Switzerland, Daniella Foster, Senior Vice President and Global Head of Public Affairs, Market Access and Sustainability, Bayer Consumer Health Division, spotlights three important ways life sciences companies can lead the charge in creating a more resilient healthcare system.
Addressing Climate Change For Better Global Health Outcomes
A new report from Oliver Wyman and WEF details how the global life sciences industry can bolster investments to combat the impact of climate change on health.
Beyond climate and health, Oliver Wyman partners were on the ground in Davos to talk about CEO strategies for transformation, boosting supply chain agility, and more. Click here for a complete digest of content.